Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Treace Medical Concepts (NASDAQ:TMCI) while lowering the price target from $7.5 to $6.
October 14, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Treace Medical Concepts and reduced the price target from $7.5 to $6, indicating a cautious outlook.
The reduction in price target from $7.5 to $6 by Truist Securities suggests a less optimistic view on Treace Medical Concepts' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100